August 30, 2007— Anesiva, Inc. (Nasdaq: ANSV) and Particle Therapeutics Limited have entered into an agreement granting Particle Therapeutics a specific-use license to incorporate Anesiva’s drug delivery technology into its needle-free, intradermal delivery system for glucagon, a hormone commonly used for the treatment of hypoglycemia associated with Type 1 and Type 2 diabetes... Anesiva's Press Release - Particle Therapeutics' Press Release -
Aug. 29, 2007 (PRIME NEWSWIRE) -- BodyTel Scientific, Inc. (OTCBB:BDYT) will be attending the first Primary Healthcare Exhibition and Congress at the Abu Dhabi National Exhibition Centre in the United Arab Emirates September 2-4. At the event, BodyTel Scientific will be showcasing their flagship telemedicine-based diabetes self-management solution, GlucoTel at booth 4D10.(...) The meter is part of the GlucoTel system, a complete telemedical diabetes self-management system supporting patients and doctors in the treatment of diabetes... read the BodyTel's Press Release. -
Aug. 27, 2007 - Pfizer Inc. (NYSE: PFE) and Bristol-Myers Squibb Company (NYSE: BMY) ("companies") have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors. Pfizer's DGAT- 1 discovery program includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes... Pfizer's Press Release. - BMS' Press Release. -
(The program also includes DGAT-1 inhibitors in-licensed by Pfizer from Bayer Pharmaceuticals Corporation in June 2006, including a pre-clinical compound (known as PF-04415060 or BAY 74-4113) originally discovered by Bayer.) 14 June 2006 Bayer Pharma's Press Release.
August 23, 2007 - Teijin Pharma Limited ("Teijin") and Chugai Pharmaceutical Co., Ltd. ("Chugai") have concluded a collaboration agreement to develop 
an anti-diabetic drug ITM-077 (Ipsen development code: BIM 51077, Roche and Chugai development code: R1583) in Japan originated by Ipsen (stock code Euronext: IPN) ... Teijin's Press Release - Chugai's Press Release -
August 23, 2007 - Cannasat Therapeutics Inc. ("Cannasat") (TSX-V: CTH), announced that Health Canada has approved Cannasat’s clinical trial application for a Phase 1 clinical study with its lead product, CAT 310, its first cannabinoid based product that is designed to help manage neuropathic pain and other disorders... Neuropathic pain can be caused by many common diseases such as diabetes... Cannasat Therapeutics' Press Release.
AtheroGenics, Inc. (
August 21, 2007 – Medtronic, Inc. (NYSE: MDT) announced an exclusive United States agreement with LifeScan, Inc., a Johnson & Johnson (NYSE: JNJ) company, to distribute and co-market new blood glucose meters to be developed by LifeScan for Medtronic Diabetes patients.
Aug. 21, 2007--Sirtris Pharmaceuticals (NASDAQ: SIRT), a biopharmaceutical company announced the initiation of a Phase 2a clinical trial to evaluate its SRT501 product candidate in patients with Type 2 Diabetes whose glucose levels are not adequately controlled by their metformin treatment... Sitris' Press Release
August 21, 2007 - Medtronic, Inc. (NYSE: MDT) and Bayer Diabetes Care, a division of Bayer HealthCare LLC and a member of the Bayer Group (NYSE: BAY), announced an alliance to distribute and co-market a new blood glucose meter for Medtronic patients outside the United States beginning in Canada and Europe. Medtronic's Press Release or Bayer' Press Relase (news from the Bayer Press Service)
Novo Nordisk (20 August 2007) announced clinical results from the second and third of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The two 26-week studies are part of the LEAD® (Liraglutide Effect and Action in Diabetes)... -> click here to read the Novo Nordisk's Press Release. (PDF Version)
UCB announced [17 August 2007] that an application for marketing authorization (MAA) for Vimpat® (lacosamide) as therapy for diabetic neuropathic pain has been submitted to the European Medicines Agency (EMEA) by UCB's subsidiary SCHWARZ PHARMA and has been accepted for review[...] link to the complete press release
Oramed (OTCBB: ORMP) is developing an orally ingestible soft gel insulin capsule for the treatment of diabetes and it has successfully completed its exploratory Phase 1A clinical trial... click here for the Oramed's press release.
Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of chronic neurological conditions, today announced it received approval from the U.S. Food and Drug Administration (FDA) to proceed with the U.S. clinical development of AV411 (ibudilast)...Avigen is currently conducting a Phase IIa study of AV411 in Australia for the treatment of diabetic neuropathic pain and was recently approved by the FDA to initiate a large Phase I clinical trial in the United States...
